ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)

Inclusion Criteria: * Subjects will be eligible if the following criteria are met: * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age \> 50 years * Patient related considerations * Able to maintain follow-up for at least 24 months. * Women must be postmenopausal without a period for at least one year. * Diagnosed with Age-related Macular Degeneration (ARMD) with active subfoveal choroidal neovascular membrane (CNVM), newly diagnosed or treated with first dose of anti-VEGF therapy within 6 weeks of enrollment * Visual acuity 20/40 to 20/400 * Lesion size \< 12 Disc Area * Submacular hemorrhage less than 75% of total lesion and not involving foveal center * Submacular fibrosis less than 25% of total lesion * Candidate for intravitreal anti-VEGF therapy Exclusion Criteria: * Subjects who meet any of the following criteria will be excluded from this study: * Prior enrollment in the study * Pregnancy (positive pregnancy test) or lactation * Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated * Participation in another simultaneous medical investigation or trial * Previous treatment with Photodynamic Therapy (PDT) or thermal laser in study eye * Anti-VEGF therapy within 6 weeks * Intravitreal or subtenon's Kenalog within 6 months * Intraocular surgery within 3 months or expected in the next 6 months * Current or planned participation in other experimental treatments for wet AMD * Other concurrent retinopathy or optic neuropathy * Other causes of CNVM, i.e. myopic degeneration or ocular histoplasmosis (POHS) * Significant media opacity precluding adequate view of the fundus for exam, photography or OCT * History of radiation therapy to the head or study eye * Diabetes mellitus or hemoglobin A1c \> 6 * Head tremor or h/o claustrophobia precluding positioning for proton irradiation * Inability to maintain steady fixation with either eye * History of Malignancy treated within 5 years * Allergy to Fluorescein dye